Abstract

The aim of this study was to evaluate which administration timing of valsartan provides satisfactory blood pressure (BP) control, once daily in the morning, once daily in the evening, or twice daily in total 160 mg. Hypertensive patients with mild-to-moderate diabetic nephropathy were enrolled, but those with more than three anti-hypertensive agents, renal insufficiency (serum creatinine ≥ 3 mg/ dL), or hepatic insufficiency were excluded. They were randomized to receive valsartan 160mg once daily in the morning, valsartan 160 mg once daily in the evening, or valsartan 80 mg twice daily for 12 weeks according to a three-period crossover design. Office blood pressure (OBP), home blood pressure (HBP) self-measured by patients, and urinary albumin excretion adjusted by creatinine excretion (UAE) were measured every 12 weeks. In 34 patients, (male: 18, mean age: 57.5 ± 10.3), valsartan with ether all administration timing demonstrated significant reductions in OBP and HBP compared to baseline: valsartan 160 mg once daily in the morning: −12.2/−9.5 mmHg (p < 0.01); valsartan 160 mg once daily in the evening: −14.2/−10.3 mmHg (p < 0.01); valsartan 80 mg twice daily: −15.0/−10.2 mmHg (p < 0.01) There was no statistically significant differences in a decrease in OBP and HBP, and reduction of UAE among three administration timing. In conclusion, these data indicate that the efficacy on BP-lowering does not depend on administration timing of valsartan in patients with diabetic nephropathy.

Highlights

  • It has been increasingly recognized that diabetic patients with hypertension are at a very high risk of cardiovascular disease

  • We evaluated the dosing time- or dosing frequency-related difference in the efficacy of valsartan, an ARB, at the maximum daily dose of 160 mg in hypertensive patients with type 2 diabetes

  • In hypertensive patients with type 2 diabetes who could not achieve the target blood pressure (BP) (

Read more

Summary

Introduction

It has been increasingly recognized that diabetic patients with hypertension are at a very high risk of cardiovascular disease. It is, reported that diabetic patients have a 2- to 4-fold higher risk of cardiovascular disease than nondiabetic patients, with a further 2- to 3-fold increased risk of cardiovascular disease in the presence of hypertension [1, 2]. Cardiovascular events occur more frequently in the early morning, and morning BP is significantly correlated with the overall cardiovascular risk involving the brain, heart, and kidney, indicating that it is important to control morning hypertension [6]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call